By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

Immunic Therapeutics says it's "on track" in its MS clinical trials of vidofludimus calcium, with CALLIPER top-line data ...

DIET plays an important role when it comes to overall health, providing the necessary nutrients to support bodily functions and maintain energy levels. It can also significantly reduce the risk of ...

The activation of the NLRP3 inflammasome has been associated with the pathogenesis of AD, therefore, targeting NLRP3 may help reduce neuroinflammation and slow down the progression of AD.

Recent research has uncovered a link between diet, blood sugar control, and brain health in aging adults. The study, ...

Recent studies have identified the significance of mitophagy, a quality control process that removes dysfunctional ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Glaucoma is a progressive eye disorder characterized by fluid buildup inside the eye, causing ocular hypertension. By 2040, ...

Huntington’s Disease (HD) is a fatally inherited neurodegenerative, orphan disorder affecting 1 in 10,000 individuals with a higher prevalence in Caucasian race. HD is caused by an expanded glutamine ...

Oculis Holding ( (OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic ...